معرفی
Daniel McNaughton is a Research Fellow at the Monash Institute of Pharmaceutical Sciences, Monash University, working in the laboratory of Professor Peter Scammells. His research focuses on the development of allosteric and bitopic ligands for G protein-coupled receptors (GPCRs), particularly the M1 and M4 muscarinic receptor subtypes, which hold therapeutic promise for neurodegenerative and psychiatric disorders including Alzheimer’s disease and schizophrenia.
Education:
- PhD in Chemistry, University of Sydney (awarded January 5, 2022)
- Master’s in Chemistry, University of Oxford (awarded July 7, 2017)
His research integrates synthetic medicinal chemistry with pharmacological profiling and structure-based design. His expertise spans Medicinal Chemistry, GPCR pharmacology, allosteric modulation, and supramolecular chemistry. He previously completed his PhD under Professor Phil Gale at the University of Sydney, where he designed synthetic anion transporters capable of translocating anions across lipid bilayers, employing vesicle-based assays and cell studies to evaluate their activity and mechanisms.
Daniel has co-authored over 20 peer-reviewed publications and has contributed to interdisciplinary research projects. His work bridges fundamental chemical design with biological application, aiming to improve therapeutic targeting through innovative ligand development.
Scientific Awards:
Daniel has assisted in the supervision of multiple Honours students during his PhD and postdoctoral work, demonstrating commitment to academic mentoring. While specific grants are not listed, his research trajectory suggests active involvement in funded projects related to drug discovery and receptor pharmacology.
He is part of a leading medicinal chemistry research group at Monash, contributing to cutting-edge efforts in developing novel therapeutics for central nervous system disorders.
